Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Sarcoma 1Dermatologic 1

Conditions

Sarcoma, Synovial 2Sarcoma 2Melanoma 2Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 3aflibercept 2Taxes 2Specimen Handling 2Psychiatric Rehabilitation 2Magnetic Resonance Spectroscopy 2Gene Expression Profiling 2Fentanyl 2Cisplatin 2Carboplatin 2tinostamustine 1sodium thiosulfate 1rucaparib 1pelcitoclax 1motexafin lutetium 1entinostat 1cobimetinib 1X-Rays 1Topotecan 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Serotonin Plasma Membrane Transport Proteins 1Ropivacaine 1Radiotherapy 1Radiation 1Quality of Life 1Polymerase Chain Reaction 1Platinum 1Patient Reported Outcome Measures 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Decitabine × Sarcoma × Clear all
NCT02650986 2025-06-17

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
15 enrolled 12 charts
DermatologicGynecologicSarcoma

Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡